Table 3.
Adjusteda Length of Stay and Opioid Consumption in the Hospital Setting, 2013–2014
| Parameter | Surgery | Liposomal bupivacaine cohort | No liposomal bupivacaine cohort | Ratio (95% CI)b | P value | ||
|---|---|---|---|---|---|---|---|
| Patients, N | LSM (95% CI) | Patients, N | LSM (95% CI) | ||||
| Hours at facility (length of stay)c | THA | 75 | 28.90 (24.62–33.93) | 103 | 41.11 (34.60–48.86) | 0.70 (0.61–0.81) | <.0001 |
| TKA | 148 | 27.94 (22.76–34.30) | 75 | 40.76 (32.49–51.13) | 0.69 (0.61–0.78) | <.0001 | |
| THA + TKA | 223 | 30.41 (25.52–36.24) | 178 | 43.61 (36.20–52.54) | 0.70 (0.64–0.76) | <.0001 | |
| Total in-hospital opioid consumption, morphine milligram equivalent | THA | 75 | 85.8 (65.4–112.7) | 103 | 91.9 (68.4–123.4) | 0.93 (0.73–1.20) | .5951 |
| TKA | 148 | 82.2 (55.4–122.0) | 75 | 116.4 (75.2–180.0) | 0.71 (0.55–0.90) | .0056 | |
| THA + TKA | 223 | 96.2 (69.7–133.0) | 178 | 123.6 (87.8–173.9) | 0.78 (0.66–0.92) | .0035 | |
a
The analytic model was adjusted for age, sex, type of surgery, year of surgery, class of insurance, cardiovascular disease/diabetes condition, and tobacco use.
b
Liposomal bupivacaine versus no liposomal bupivacaine.
c
Hours at facility defined as check into the facility to discharge from the facility.
CI indicates confidence interval; LSM, least squares mean; THA, total hip arthroplasty; TKA, total knee arthroplasty.